| Autor: |
Kesavan, Murali, Zammar, Ghassan, McQuillan, James T., Macdonald, William B. G., Turner, J. Harvey, McQuillan, Andrew D. |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology; Jan2022, Vol. 196 Issue 1, p237-241, 5p |
| Abstrakt: |
First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. Keywords: radioimmunotherapy; MDS; acute leukaemia; follicular lymphoma; haemotoxicity EN radioimmunotherapy MDS acute leukaemia follicular lymphoma haemotoxicity 237 241 5 12/27/21 20220101 NES 220101 Advances in the treatment of follicular lymphoma (FL) have fostered the hope that some patients may be cured with the use of immunochemotherapy. Fractionated 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text